Affecting HEK293 Cell Growth and Production Performance by Modifying the Expression of Specific Genes.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
02 07 2021
Historique:
received: 24 04 2021
revised: 24 06 2021
accepted: 28 06 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 27 10 2021
Statut: epublish

Résumé

The HEK293 cell line has earned its place as a producer of biotherapeutics. In addition to its ease of growth in serum-free suspension culture and its amenability to transfection, this cell line's most important attribute is its human origin, which makes it suitable to produce biologics intended for human use. At the present time, the growth and production properties of the HEK293 cell line are inferior to those of non-human cell lines, such as the Chinese hamster ovary (CHO) and the murine myeloma NSO cell lines. However, the modification of genes involved in cellular processes, such as cell proliferation, apoptosis, metabolism, glycosylation, secretion, and protein folding, in addition to bioprocess, media, and vector optimization, have greatly improved the performance of this cell line. This review provides a comprehensive summary of important achievements in HEK293 cell line engineering and on the global engineering approaches and functional genomic tools that have been employed to identify relevant genes for targeted engineering.

Identifiants

pubmed: 34359846
pii: cells10071667
doi: 10.3390/cells10071667
pmc: PMC8304725
pii:
doi:

Substances chimiques

Recombinant Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nat Struct Mol Biol. 2008 Jul;15(7):658-64
pubmed: 18618939
Biotechnol Prog. 2005 Jan-Feb;21(1):106-11
pubmed: 15903247
Mol Membr Biol. 2013 Feb;30(1):52-63
pubmed: 22963530
PLoS One. 2015 Apr 20;10(4):e0123562
pubmed: 25893827
Biotechnol Bioeng. 2004 Feb 5;85(3):340-50
pubmed: 14748090
Biotechnol Bioeng. 2002 Mar 20;77(6):704-16
pubmed: 11807766
Front Immunol. 2013 Jul 29;4:217
pubmed: 23908655
J Cell Physiol. 1994 Oct;161(1):71-6
pubmed: 7929610
MAbs. 2009 May-Jun;1(3):230-6
pubmed: 20065644
Biotechnol Bioeng. 2015 Aug;112(8):1632-43
pubmed: 25676429
J Cell Physiol. 1988 Apr;135(1):151-5
pubmed: 3130381
Appl Biochem Biotechnol. 1993 Nov;43(2):93-116
pubmed: 8267405
Nat Biotechnol. 2010 Aug;28(8):863-7
pubmed: 20657583
Cell. 2003 Feb 21;112(4):519-33
pubmed: 12600315
J Immunol Methods. 2016 Dec;439:50-58
pubmed: 27677581
J Biotechnol. 2008 Jun 1;135(2):217-23
pubmed: 18448183
Mol Ther. 2016 Feb;24(2):287-297
pubmed: 26437810
BMC Biotechnol. 2013 Jun 26;13:52
pubmed: 23802841
BMC Biotechnol. 2007 Oct 18;7:71
pubmed: 17945021
Curr Opin Struct Biol. 2013 Jun;23(3):345-56
pubmed: 23623336
J Biotechnol. 2010 Apr 15;146(4):160-8
pubmed: 20188772
Blood. 2005 Dec 1;106(12):3811-5
pubmed: 16081695
Biotechnol Bioeng. 1998 Mar 5;57(5):518-28
pubmed: 10099230
Biotechnol J. 2020 Sep;15(9):e1900562
pubmed: 32639642
Methods Mol Biol. 2018;1850:209-219
pubmed: 30242689
Biotechnol Bioeng. 2003 Feb 5;81(3):329-40
pubmed: 12474256
PLoS Biol. 2018 Nov 27;16(11):e2006951
pubmed: 30481169
N Biotechnol. 2020 Jan 25;54:28-33
pubmed: 31425885
Traffic. 2008 Jun;9(6):861-70
pubmed: 18315532
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Cytotechnology. 1990 May;3(3):215-29
pubmed: 1366658
Mol Ther Methods Clin Dev. 2016 Mar 30;3:16015
pubmed: 27069949
J Biosci Bioeng. 2019 Oct;128(4):487-494
pubmed: 31031194
Nat Biotechnol. 2014 May;32(5):485-9
pubmed: 24752077
BMC Biotechnol. 2008 Aug 27;8:65
pubmed: 18752669
Crit Rev Biotechnol. 2018 Sep;38(6):851-867
pubmed: 29262720
Biotechnol J. 2018 Feb;13(2):
pubmed: 28987030
Mol Med Rep. 2016 Sep;14(3):2257-63
pubmed: 27430244
Signal Transduct Target Ther. 2021 Feb 8;6(1):53
pubmed: 33558455
Biotechniques. 2003 Jan;34(1):184-9
pubmed: 12545558
Metab Eng. 2013 Nov;20:131-45
pubmed: 24120735
Biotechnol Bioeng. 2008 Jun 1;100(2):273-83
pubmed: 18512821
Biotechnol Bioeng. 2021 Apr;118(4):1649-1663
pubmed: 33463716
Protein Expr Purif. 2012 Jul;84(1):147-53
pubmed: 22580292
Biotechnol Bioeng. 2018 May;115(5):1367-1372
pubmed: 29359789
Biotechnol Bioeng. 2017 Nov;114(11):2539-2549
pubmed: 28710851
Methods. 2011 Dec;55(4):273-80
pubmed: 21925269
Biotechnol Prog. 2003 Jan-Feb;19(1):90-7
pubmed: 12573011
Front Physiol. 2016 Jul 19;7:300
pubmed: 27486406
J Biochem. 2019 Sep 1;166(3):245-258
pubmed: 31102532
Nat Biotechnol. 2014 May;32(5):443-5
pubmed: 24811516
Nat Protoc. 2018 Jan;13(1):99-117
pubmed: 29240734
N Biotechnol. 2015 Dec 25;32(6):673-9
pubmed: 25529337
Metab Eng. 2010 Nov;12(6):526-36
pubmed: 20826224
Gene Ther. 2010 Apr;17(4):503-10
pubmed: 19956269
Med Sci (Basel). 2018 Jun 08;6(2):
pubmed: 29890687
Biotechnol Bioeng. 2016 Nov;113(11):2403-15
pubmed: 27215166
Hum Gene Ther Methods. 2016 Jun;27(3):112-21
pubmed: 27229773
J Biotechnol. 2017 Jan 20;242:73-82
pubmed: 27940295
J Biol Chem. 2018 Apr 13;293(15):5572-5584
pubmed: 29475941
Biotechnol J. 2016 Feb;11(2):290-7
pubmed: 26284700
Nat Biotechnol. 2003 Oct;21(10):1208-14
pubmed: 12960965
BMC Biotechnol. 2015 May 16;15:31
pubmed: 25981500
Metab Eng. 2011 Sep;13(5):499-507
pubmed: 21624497
Biotechnol Prog. 1998 May-Jun;14(3):410-9
pubmed: 9622521
Biotechnol Bioeng. 2004 Nov 20;88(4):474-88
pubmed: 15459912
J Virol Methods. 2006 Dec;138(1-2):85-98
pubmed: 16950522
PLoS One. 2012;7(8):e43394
pubmed: 22937046
J Biochem. 2021 Apr 20;:
pubmed: 33878161
Sci Rep. 2020 Nov 4;10(1):18996
pubmed: 33149219
J Virol Methods. 2014 Feb;196:163-73
pubmed: 24239634
Methods Enzymol. 1993;222:450-77
pubmed: 8412810
Gene. 2015 Sep 15;569(2):182-90
pubmed: 26026906
J Biotechnol. 2014 Jan;169:63-70
pubmed: 24246270
Vaccine. 2010 May 7;28(21):3661-71
pubmed: 20347632
J Gene Med. 2009 Oct;11(10):868-76
pubmed: 19618482
Thromb Res. 2008;122(3):405-10
pubmed: 18177690
BMC Biotechnol. 2015 Sep 18;15:87
pubmed: 26382581
Biotechnol Bioeng. 2021 Jan;118(1):186-198
pubmed: 32910455
Curr Opin Biotechnol. 2021 May 28;71:18-24
pubmed: 34058525
Biotechnology (N Y). 1991 Dec;9(12):1347-55
pubmed: 1367768
Biotechnol Prog. 2000 Sep-Oct;16(5):736-43
pubmed: 11027164
Nat Commun. 2014 Sep 03;5:4767
pubmed: 25182477
Biosens Bioelectron. 2001 Sep;16(7-8):603-8
pubmed: 11544055
Biologicals. 2015 Jul;43(4):213-9
pubmed: 26094124
Haemophilia. 2014 Jul;20(4):e327-35
pubmed: 24811361
Nucleic Acids Res. 2008 Sep;36(15):e96
pubmed: 18617574
J Biotechnol. 2016 Dec 10;239:57-60
pubmed: 27725209
Protein Sci. 2014 May;23(5):517-25
pubmed: 24510886
Eur J Haematol. 2012 Aug;89(2):165-76
pubmed: 22690791
J Gen Virol. 1977 Jul;36(1):59-74
pubmed: 886304
Acta Crystallogr D Struct Biol. 2020 Dec 1;76(Pt 12):1244-1255
pubmed: 33263330
Metab Eng. 2010 Jan;12(1):18-25
pubmed: 19723587
Metab Eng. 2020 May;59:98-105
pubmed: 32061967
Biotechnol Bioeng. 1988 Aug 5;32(4):491-506
pubmed: 18587747
J Thromb Haemost. 2013 Jan;11(1):132-41
pubmed: 23205847
Biotechnol Bioeng. 2009 Nov 1;104(4):752-65
pubmed: 19623569
Metab Eng. 2006 May;8(3):264-72
pubmed: 16635796
Methods. 2002 Oct;28(2):158-67
pubmed: 12413414
Biotechnol Bioeng. 2007 Apr 15;96(6):1155-66
pubmed: 17058277
Biomaterials. 2007 Dec;28(35):5369-80
pubmed: 17764735
Hum Gene Ther Methods. 2019 Feb;30(1):23-33
pubmed: 30693792
Wellcome Open Res. 2019 Aug 9;4:119
pubmed: 32030357
J Biol Chem. 2000 Sep 22;275(38):29488-502
pubmed: 10867010
Appl Microbiol Biotechnol. 2007 Sep;76(3):659-65
pubmed: 17583807
Crit Rev Biotechnol. 2016 Dec;36(6):1110-1122
pubmed: 26383226
Curr Opin Biotechnol. 2006 Aug;17(4):381-6
pubmed: 16806893
Mol Ther Methods Clin Dev. 2018 Mar 29;9:278-287
pubmed: 29707602
Biotechnol Bioeng. 1992 Feb 20;39(4):418-31
pubmed: 18600963
Mol Biotechnol. 2019 May;61(5):317-324
pubmed: 30790232
Appl Microbiol Biotechnol. 2015 Dec;99(23):9935-49
pubmed: 26278533
J Pharmacol Toxicol Methods. 2005 May-Jun;51(3):187-200
pubmed: 15862464
Biotechnol Bioeng. 2016 Jan;113(1):150-62
pubmed: 26134455
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13419-24
pubmed: 12370423
Biotechnol Prog. 2005 May-Jun;21(3):664-70
pubmed: 15932240
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29
pubmed: 17565364
J Proteome Res. 2020 Mar 6;19(3):1085-1099
pubmed: 31994890
Biotechnol J. 2021 May;16(5):e2000351
pubmed: 33314785
Methods Enzymol. 2009;463:223-38
pubmed: 19892175
Mol Ther Methods Clin Dev. 2014 Aug 13;1:14034
pubmed: 26015974
Biotechnol Bioeng. 2009 Mar 1;102(4):1170-81
pubmed: 18989903
Sci Rep. 2019 Nov 14;9(1):16768
pubmed: 31727983
Thromb Res. 2013 Jan;131(1):78-88
pubmed: 23058466
MAbs. 2019 Jul;11(5):977-986
pubmed: 30907238
Biotechnol Bioeng. 2008 Jan 1;99(1):155-64
pubmed: 17614336

Auteurs

Laura Abaandou (L)

Biotechnology Core Laboratory National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
Department of Chemistry and Biochemistry, College of Science, George Mason University, Fairfax, VA 22030, USA.

David Quan (D)

Biotechnology Core Laboratory National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.

Joseph Shiloach (J)

Biotechnology Core Laboratory National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH